Loading
The radioactive sugar used in almost every cancer PET scan, approved in the 1990s and made fresh each day by regional cyclotrons.
Fludeoxyglucose F-18 was the first PET radiopharmaceutical approved by the FDA (1994, initially for epilepsy foci and cardiac viability) and gained its oncology indication in 2000 for assessing abnormal glucose metabolism to assist in evaluating malignancy in patients with known or suspected cancer. It is produced under multiple abbreviated NDAs by commercial and academic cyclotron networks (PETNET, Cardinal Health, SOFIE, hospital sites) and is the tracer behind staging, response assessment (Deauville in lymphoma, PERCIST) and surveillance across most solid tumours. Its weaknesses, uptake in inflammation and poor sensitivity for indolent or low-glucose tumours, drive the development of target-specific tracers.
18F-labelled glucose analogue taken up through GLUT transporters and trapped after phosphorylation by hexokinase, so metabolically active tumours accumulate signal.
1.Fludeoxyglucose F-18 (FDG) slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 1994 | First FDG NDA (neurology and cardiology indications) |
| US | 2000 | Oncology: assessment of abnormal glucose metabolism to assist in evaluating malignancy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Fludeoxyglucose F-18" OR ABSTRACT:"Fludeoxyglucose F-18" OR TITLE:"FDG" OR ABSTRACT:"FDG" OR TITLE:"multiple manufacturers" OR ABSTRACT:"multiple manufacturers") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Fludeoxyglucose F-18 (FDG), not a curated reading list.
Shares PET/CT and the tag test.
Shares PET/CT and the tag test.
Shares PETNET Solutions (Siemens Healthineers), Cardinal Health Nuclear & Precision Health Solutions, SOFIE Biosciences, PET (positron emission tomography).
Shares PETNET Solutions (Siemens Healthineers), Cardinal Health Nuclear & Precision Health Solutions, SOFIE Biosciences, PET (positron emission tomography).
Shares PETNET Solutions (Siemens Healthineers), Cardinal Health Nuclear & Precision Health Solutions, SOFIE Biosciences, PET (positron emission tomography).
Shares Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy, PET (positron emission tomography), PET/CT.
Shares AHOD2131 (COG / NCTN), Deauville score and PET-adapted therapy, FDG PET, PET/CT.
Shares Standardised uptake value (SUV), FDG PET, PET (positron emission tomography), PET/CT.